• Michal Weiler-Sagie
  • Ora Israel


Lymphoma is a malignancy that originates in the lymphocytes. There are many types of lymphoma, and overall they are divided into two large groups: non-Hodgkin’s lymphoma (NHL), representing the majority (approximately 85%) of these tumors, and Hodgkin’s disease (HD). Lymphomas account for about 5% of all cases of cancer in the United States, and their incidence is rising.1 A significant portion of lymphomas are curable with appropriate treatment.


Positron Emission Tomography Follicular Lymphoma Mantle Cell Lymphoma Mediastinal Mass Bone Marrow Involvement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.CrossRefPubMedGoogle Scholar
  2. 2.
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma classification project. J Clin Oncol 1998;16:2780–2795.PubMedGoogle Scholar
  3. 3.
    Adult Non-Hodgkin Lymphoma Treatment, National Cancer Institute, U.S. National Institutes of Health, last updated on 12/17/2007 (Accessed December 20th 2007, at
  4. 4.
    Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Hudson GV, Linch DC. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial.Lancet 2003;362:516–522.CrossRefPubMedGoogle Scholar
  5. 5.
    Adult Hodgkin Lymphoma Treatment, National Cancer Institute, U.S. National Institutes of Health, last updated on 7/17/2007 (Accessed December 20th 2007, at
  6. 6.
    Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, Pitsilos S, Bagg A, Downs L, Mehrotra A. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875–3876.CrossRefPubMedGoogle Scholar
  7. 7.
    Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, Saitoh T, Handa H, Endo K, Murakami H. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67Gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification.Cancer 2007;110:652–659.CrossRefPubMedGoogle Scholar
  8. 8.
    Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3509–3516.Google Scholar
  9. 9.
    Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, Moser E, Glatting G, Kotzerke J, Guhlmann CA, Schirrmeister H, Reske SN. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889–899.CrossRefPubMedGoogle Scholar
  10. 10.
    Moog F, Bangerter M, Diederichs CG, Guhlmann. A, Kotzerke J, Merkle E, Kolokythas O, Herrmann. F, Reske SN. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795–800.PubMedGoogle Scholar
  11. 11.
    Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, Reske SN. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475–481.PubMedGoogle Scholar
  12. 12.
    Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S, Nagler A, Polliack A, Ben-Bassat I, Even-Sapir E. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 2006;17:117–122.CrossRefPubMedGoogle Scholar
  13. 13.
    Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066–1074.CrossRefPubMedGoogle Scholar
  14. 14.
    Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK, Goerres GW. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging – do we need contrast-enhanced CT? Radiology 2004;232:823–829.CrossRefPubMedGoogle Scholar
  15. 15.
    Tatsumi M, Cohade C, Nakamoto Y, Fishman EK,Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005;237:1038–1045.CrossRefPubMedGoogle Scholar
  16. 16.
    Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603–609.PubMedGoogle Scholar
  17. 17.
    Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis. J Nucl Med 2005;46:958–963.PubMedGoogle Scholar
  18. 18.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.CrossRefPubMedGoogle Scholar
  19. 19.
    Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization project in Lymphoma: J Clin Oncol 2007;25:571–578.Google Scholar
  20. 20.
    Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin’s lymphoma. Pediatr Radiol 2004;34:190–198.Google Scholar
  21. 21.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol 1999;17:1244.Google Scholar
  22. 22.
    Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.PubMedGoogle Scholar
  23. 23.
    Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 2007;48 Suppl 1:19S–27S.PubMedGoogle Scholar
  24. 24.
    Haioun C, Itti E,Rahmouni A, Brice P, Rain J-D, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381.CrossRefPubMedGoogle Scholar
  25. 25.
    Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen A-M, Berthelsen AK, Specht L. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–59.CrossRefPubMedGoogle Scholar
  26. 26.
    Avril NE,Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005;43:189–204.CrossRefPubMedGoogle Scholar
  27. 27.
    Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W, Vellenga E. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.Blood 2007;109:486–491.CrossRefPubMedGoogle Scholar
  28. 28.
    Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652–4661.CrossRefPubMedGoogle Scholar
  29. 29.
    Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke W-G, Ehninger G.Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115:793–800.CrossRefPubMedGoogle Scholar
  30. 30.
    Weihrauch MR, Re D, Scheidhauer K, Ansén S, Dietlein M, Bischoff S, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930–2934.CrossRefPubMedGoogle Scholar
  31. 31.
    Bar-Shalom R. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.Radiol Clin North Am 2007;45:677–688, vi–vii.CrossRefPubMedGoogle Scholar
  32. 32.
    Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005;25:191–207.CrossRefPubMedGoogle Scholar
  33. 33.
    Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005;32:749–756.CrossRefPubMedGoogle Scholar
  34. 34.
    Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ 997;314:343–346.PubMedGoogle Scholar
  35. 35.
    Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies. J Clin Oncol 1997;15:1123–1130.PubMedGoogle Scholar
  36. 36.
    Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123–130.CrossRefPubMedGoogle Scholar
  37. 37.
    Elis A, Blickstein D, Klein O, Eliav-Ronen R, Manor Y, Lishner M. Detection of relapse in non-Hodgkin's lymphoma: Role of routine follow-up studies. Am J Hematol 2002;69:41–44.CrossRefPubMedGoogle Scholar
  38. 38.
    Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:123–125.CrossRefPubMedGoogle Scholar
  39. 39.
    Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175–183.CrossRefPubMedGoogle Scholar
  40. 40.
    Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, Larson SM, Yeung HW. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643–4651.CrossRefPubMedGoogle Scholar
  41. 41.
    Podoloff DA, Advani RH, Allred C, Benson AB, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW, Hillner BE, Hoffman JM, Keil K, Komaki R, Larson SM, Mankoff DA, Rozenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD.NCCN Task Force Report: Positron Emission Tomography (PET/Computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5 Suppl 1:S1–S22.PubMedGoogle Scholar
  42. 42.
  43. 43.
    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman E, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF.Recommendations for the use of FDG (fluorine-18, (2-[18 F]Fluoro-2-deoxy-D-glucose) positron emission tomography in oncology. J Nucl Med 2008;49:480–508.CrossRefPubMedGoogle Scholar
  44. 44.
    Soudack M, Bar-Shalom R, Israel O, Ben-Arie Y, Levy Z, Gaitini D.Utility of sonographically guided biopsy in metabolically suspected recurrent lymphoma. J Ultrasound Med 2008;27:225–231.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Nuclear MedicineRambam Health Care CampusHaifaIsrael
  2. 2.Rambam Health Care Campus, B. and R. Rappaport School of Medicine, Technion, Israel Institute of TechnologyHaifaIsrael

Personalised recommendations